التفاصيل البيبلوغرافية
| العنوان: |
Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. |
| المؤلفون: |
Bonotto, Marta, Gerratana, Lorenzo, Poletto, Elena, Driol, Pamela, Giangreco, Manuela, Russo, Stefania, Minisini, Alessandro M., Andreetta, Claudia, Mansutti, Mauro, Pisa, Federica E., Fasola, Gianpiero, Puglisi, Fabio |
| المصدر: |
Oncologist; 2014, Vol. 19 Issue 6, preceding, following p608-615, 10p, 5 Charts, 2 Graphs |
| مصطلحات موضوعية: |
BREAST tumor treatment, METASTASIS, CANCER treatment, ACADEMIC medical centers, BREAST tumors, CONFIDENCE intervals, HEALTH outcome assessment, RESEARCH funding, SURVIVAL analysis (Biometry), SURVIVAL, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics |
| مصطلحات جغرافية: |
ITALY |
| مستخلص: |
No gold standard treatment exists for metastatic breast cancer (MBC). Clinical decision making is based on knowledge of prognostic and predictive factors that are extrapolated from clinical trials and, sometimes, are not reliably transferable to a real-world scenario. Moreover, misalignment between endpoints used in drug development and measures of outcome in clinical practice has been noted.The roles of overall survival (OS) and progression-free survival (PFS) as primary endpoints in the context of clinical trials are the subjects of lively debate. Information about these parameters in routine clinical practice is potentially useful to design new studies and/or to interpret the results of clinical research. This study analyzed the impact of patient and tumor characteristics on the major measures of outcome across different lines of treatment in a cohort of 472 patients treated for MBC. OS, PFS, and postprogression survival (PPS) were analyzed.The study showed how biological and clinical characteristics may have different prognostic value across different lines of therapy for MBC. After first-line treatment, the median PPS of luminal A, luminal B, and human epidermal growth factor receptor 2 (HER2)-positive groups was longer than 12 months. The choice of OS as a primary endpoint for clinical trials could not be appropriate with these subtypes. In contrast, OS could be an appropriate endpoint when PPS is expected to be low (e.g., triple-negative subtype after the first line; other subtypes after the third line). The potential implications of these findings are clinical and methodological. [ABSTRACT FROM AUTHOR] |
|
Copyright of Oncologist is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder